tradingview.comNov 4

CeriBell, Inc. Stock 12‑Month Price Target Raised to $31.57, Implies 12% Upside

CeriBell, Inc.'s average stock price target increased from $29.57 to $31.57, according to 7 analysts, with a potential 12% upside from the Nov. 3 closing price. The consensus rating remains 'Buy' across 8 analysts.

Original reporting

tradingview.com

Published Nov 4, 2026, 10:20 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Nov 4, 2026, 10:28 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

CeriBell, Inc. Stock 12‑Month Price Target Raised to $31.57, Implies 12% Upside — source image — Source · tradingview.com

Decision brief

The 30-second read

Med

Timing

today

Relevance 5/10Novelty 6/10Timing: today

Read at source ← All news

$CBLLMedAI 8/10

CeriBell Inc (CBLL) (Q3 2026) Earnings Call Highlights: Record Hospital Additions

CeriBell Inc (CBLL) reported Q3 2026 revenue of $29.3M, up 30% YoY, with 35 new hospitals added. Gross margin improved to 90%, but net loss widened to $21.4M. Full-year guidance raised to $115-$117M. Delirium monitoring pilot showed clinical impact, but no material revenue contribution yet. Operating expenses rose 36% YoY. CEO Jane Chao and CFO Scott Blomberg discussed growth strategies and 2027 outlook.

finance.yahoo.comNov 4

$CBLLHigh

Ceribell Reports Third Quarter 2026 Financial Results

Ceribell, Inc. (CBLL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Ceribell Reports Third Quarter 2026 Financial Results Sunnyvale, Calif. – November 3, 2026 – CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today repor

SEC EDGAR 8-KNov 3

$EWHighAI 8/10

Weekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report Data

Edwards Lifesciences (EW) received FDA approval for a pediatric heart valve. Ceribell (CBLL) and SI-BONE (SIBN) cleared new software and spinal fusion systems. Teva (TEVA) added a biosimilar to its portfolio. AbbVie (ABBV) and Mirum (MIRM) gained FDA approvals for Parkinson's and rare disease treatments. Merck (MRK) withdrew a lung cancer drug filing. Sanofi (SNY) and Regeneron (REGN) expanded their immunology alliance.

rttnews.comOct 2

$CBLLMed

Ceribell Gains FDA Clearance For New EEG Monitoring Software

Ceribell, Inc. (CBLL) announced FDA clearance for new EEG monitoring software. The update includes Alpha-Delta Ratio, Relative Alpha, and Burst Suppression monitoring, aiding clinicians in tracking brain activity. The software will be available via update in early 2027. CBLL stock closed at $24.86, up 1.43%.

rttnews.comSep 30

$CBLLMedAI 8/10

Ceribell Receives FDA 510(k) Clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis

Ceribell, Inc. (Nasdaq: CBLL) received FDA 510(k) clearance for new software for its EEG system, enabling easier interpretation of brain activity trends. The update includes Alpha-Delta Ratio, Burst Suppression, and Amplitude-Integrated EEG monitoring, applicable to patients of all ages. The company expects to roll out the features in the first half of 2027.

globenewswire.comSep 30

$BLSMHighAI 8/10

Biotech Stocks At 52-Week Highs - BLSM +18% On Positive Trial Data, ADPT, ILMN, CBLL, NEOG

Biotech stocks BLSM, NEOG, ILMN, CBLL, and ADPT hit 52-week highs. BLSM rose 18% on positive trial data, NEOG grew 2% with Q4 revenue of $225M, ILMN reached $236 on 9.5% Q2 growth, CBLL hit $25.63 with Q2 revenue up 33%, and ADPT climbed 3% with full-year revenue forecast between $268M-$278M.

rttnews.comSep 17